OncoMatch/Clinical Trials/NCT06433947
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Is NCT06433947 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including OPN-6602 and Dexamethasone for relapsed multiple myeloma.
Treatment: OPN-6602 · Dexamethasone — Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: immunomodulatory agent — multiple myeloma
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included immunomodulatory agents
Must have received: proteasome inhibitor — multiple myeloma
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included ... proteosome inhibitors
Must have received: anti-CD38 antibody — multiple myeloma
Relapsed or refractory to 3 or more different prior lines of therapy for MM that included ... anti-CD38 antibody
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson · Gilbert, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- Stanford Cancer Institute · Stanford, California
- Emory Winchip Cancer Center · Atlanta, Georgia
- University of Kansas Clinical Research Center · Westwood, Kansas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06433947 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received immunomodulatory agent and proteasome inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages